Cormedix Revenue
Pharmaceutical Manufacturing • 
Berkeley Heights, New Jersey, United States • 51-100 Employees
Cormedix revenue & valuation
| Annual revenue | $121,500,000 |
| Revenue per employee | $1,321,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $388,800,000 |
| Total funding | $90,000,000 |
Key Contacts at Cormedix
Michael Bannister
Area Business Director
Thomas Wiedemann
Supply Chain Director
Alan Green
Us Sales Director Cormedix In Partnership With Syneos Health
Dikesh K. Patel
Senior Director, Hospitals & Health Systems Implementation & Medical Outcomes Liaison
Justin Pettigrew
Senior Director National Accounts
Bruce Walterick
Area Sales Director → Driving Idn Account Strategy & Market Expansion In Acute Care
Philip Williams
Director Supply Chain And It Implementation
Shannon Moore
National Account Director
Alisha Allen
Senior Director Field Medical Affairs
John Perry
National Account Director
Company overview
| Headquarters | 300 Connell Dr, Suite 4200, Berkeley Heights, New Jersey 07922, US |
| Phone number | +19085179500 |
| Websites | |
| NAICS | 3254 |
| SIC | 283 |
| Founded | 2006 |
| Employees | 51-100 |
| Socials |
Cormedix Email Formats
Cormedix uses 3 email formats. The most common is {first name}{last name} (e.g., johndoe@cormedix.com), used 88.2% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@cormedix.com | 88.2% |
{first initial}{last name} | jdoe@cormedix.com | 9.8% |
{first initial} | j@cormedix.com | 2% |
About Cormedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company is focused on developing its lead product DefenCath™, a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. DefenCath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product (QIDP), and the original New Drug Application (NDA) received priority review in recognition of its potential to address an unmet medical need. For more information, visit: www.cormedix.com.
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Cormedix has 49 employees across 10 departments.
Departments
Number of employees
Funding Data
Explore Cormedix's funding history, including investment rounds, total capital raised, and key backers.
Cormedix Tech Stack
Discover the technologies and tools that power Cormedix's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Maps
JavaScript libraries
CDN
Font scripts
JavaScript libraries
JavaScript libraries
Programming languages
Blogs
Analytics
UI frameworks
SEO
United Arab Emirates
United Kingdom
Netherlands
BelgiumFrequently asked questions
4.8
40,000 users
